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Neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease represent a huge unmet medical need. The
prevalence of both diseases is increasing, but the eﬃcacy of treatment is still very limited due to various factors including the
blood brain barrier (BBB). Drug delivery to the brain remains the major challenge for the treatment of all neurodegenerative
diseases because of the numerous protective barriers surrounding the central nervous system. New therapeutic drugs that cross
the BBB are critically needed for treatment of many brain diseases. One of the signiﬁcant factors on neurotherapeutics is the
constraint of the blood brain barrier and the drug release kinetics that cause peripheral serious side eﬀects. Contrary to common
belief, neurodegenerative and neurological diseases may be multisystemic in nature, and this presents numerous diﬃculties for
their potential treatment. Overall, the aim of this paper is to summarize the last ﬁndings and news related to liposome technology
in the treatment of neurodegenerative diseases and demonstrate the potential of this technology for the development of novel
therapeuticsandthepossibleapplicationsofliposomesinthetwomostwidespreadneurodegenerativediseases,Alzheimer’sdisease
and Parkinson’s disease.
1.Introduction
E a c hy e a r ,o v e r1 0m i l l i o np e o p l eg l o b a l l ys u ﬀer from neu-
rodegenerative diseases. This ﬁgure is expected to grow
by 20% over the next decade as the aging population
increasesand lives longer. Neurodegenerative diseases arethe
fourth leading cause of death in the developed world after
heart diseases, cancer, and stroke [1]. There are millions of
suﬀerers worldwide, and the start of the disease can occur
at any age, but it is more common among the elderly. Many
similarities appear that relate these diseases to each other on
a subcellular level [2]. Discovering these similarities oﬀers
hope for therapeutic advances that could ameliorate many
diseases simultaneously.
The most common neurodegenerative diseases are
Alzheimer’s disease, Parkinson’s disease, Lewy body demen-
tia, frontotemporal dementia, amyotrophic lateral sclerosis,
Huntington’s disease, and prion diseases [3]. The most
widely recognized are Alzheimer’s disease and Parkinson’s
disease, which are among the principal debilitating con-
ditions of the current century. Approximately 24 million
people worldwide suﬀer from dementia, 60% of cases being
duetoAlzheimer’sdisease,whichoccursin1%ofindividuals
aged 50 to 70 and dramatically increases to 50% for those
over 70 years [4]. Dramatically, these numbers are estimated
to increase to 15 million in the next 40 years [5].
Alzheimer’s disease is typiﬁed clinically by learning and
memory impairment and pathologically by gross cerebral
atrophy, indicative of neuronal loss, with numerous extracel-
lular neuritic amyloid plaques and intracellular neuroﬁbril-
larytanglesfoundpredominantlyinthefrontalandtemporal
lobes, including the hippocampus [6]. The mechanisms
underlying Alzheimer’s disease are not completely clear yet,
and there is still no cure. However, in recent years, several2 Journal of Drug Delivery
approaches aimed at inhibiting disease progression have
advanced to clinical trials. Among these, strategies targeting
theproductionandclearanceoftheamyloid-betapeptideare
the most advanced [7]. The predominant accumulation and
initial peptide deposited in the brain parenchyma is a highly
ﬁbrillogenic amyloid-beta 1-42 [8]. Oligomers appearing
before plaque deposition in an early stage of Alzheimer’s
disease pathology have been indicated as the most toxic
amyloid-beta species [9]. Targeting amyloid-beta 1-42 in all
its aggregation forms has been suggested for therapeutic and
diagnostic purposes [10, 11]. Moreover, it has been recently
demonstrated that brain and blood amyloid-beta are in
equilibrium through the BBB, and sequestration of amyloid-
beta in the blood may shift this equilibrium, drawing out the
excess from the brain [12–14].
Parkinson’s disease is a chronic and progressive neu-
rological disease, the symptoms of which include tremors,
stiﬀness and slow or hesitant speech. While the disease is
most commonly associated with older people, it is thought
that around one in ten people are diagnosed before the age
of 50. There are now almost 1.2 million people suﬀering
from Parkinson’s disease in Europe and over 1 million in US;
however, medication only provides patients with temporary
symptomatic relief, while access to care and treatment diﬀers
widely depending on where patients live [15]. Parkinson’s
disease is characterized by massive depletion of striatal
dopamine as a result of degeneration of dopaminergic neu-
rons in the substantia nigra pars compacta. Beside the lack of
dopamine at the cellular level the formation of Lewy bodies
in the substantia nigra, which are cytoplasmic inclusions
composed of ﬁbrils, ubiquitin, and alpha-synuclein may
appear [16, 17].
Pharmaceutical agents that are used to treat neurode-
generative diseases are usually administered orally, such
as donepezil, memantine, rivastigmine, galantamine and
tacrine for Alzheimer’s disease [18], or levodopa, enta-
capone, pramipexole, ropinrole, benserazide, carbidopa, tol-
capone, entacapone, selegiline, rasagiline, and saﬁnamide
for Parkinson’s disease [19]. However, most of the ingested
drugs do not reach the brain in a fully way and are, instead,
metabolized totally or partially by the liver. This ineﬃcient
utilization of drug may require ingestions of higher drug
concentrations that can produce toxic eﬀects in the heart,
liver, or kidney. Also, many therapeutic agents are poorly sol-
uble or insoluble in aqueous solutions. These drugs provide
challengestodeliverthemorallyorparentally,however,these
compounds can have signiﬁcant beneﬁts when formulated
through other technologies such as liposomes.
Drug delivery to the brain remains the major challenge
for the treatment of all neurodegenerative diseases because
of the numerous protective barriers surrounding the central
nervous system. Various strategies have been developed to
deliver drugs into the brain that would not otherwise be able
to cross the BBB. Commonly, although quite undesirable,
an intraventricular catheter is surgically implanted to deliver
a drug directly into the brain. New therapeutic drugs that
cross the BBB are critically needed for treatment of many
brain diseases. One of the signiﬁcant factors on neuro-
therapeutics is the constraint of the BBB and the drug release
kineticsthatcauseperipheralserioussideeﬀects.Contraryto
common belief, neurodegenerative and neurological diseases
may be multisystemic in nature, and this presents numerous
diﬃculties for their potential treatment. In recent years, gene
therapy has evolved as a new treatment for brain diseases,
especially for neurodegenerative diseases, where genetically
engineered cells can be used to deliver speciﬁc growth factors
to target cells. However, clinical troubles have been limiting
this technique due to insuﬃcient gene transfer, lack of
prolonged gene expression, or immunorejection of producer
cells. One promising technology is the development of new
biomaterial components with the capacity of enveloping
genetically engineered cells producing and distributing the
drug therapy, and, at the same time, to be isolated from
immune system. This technology includes, among others,
the liposomes representing a potential delivery system for
speciﬁc proteins and growth factors to brain damage, where
diﬀerent producer cells may be isolated from the microenvi-
ronmental factors [20].
Liposomes are spherical vesicle structures composed of
a uni- or multilamellar lipid bilayer surrounding internal
aqueous compartments and a relatively impermeable outer
lipophilic phospholipid bilayer (Figure 1). Liposomes have
gained considerable attention as drug delivery carriers
because they are biocompatible, nontoxic, can deliver both
hydrophilic and lipophilic drug molecules, protect their
cargo from degradation by plasma enzymes, and transport
theirloadacrossbiologicalmembranesandtheBBB[21,22].
Overall, this paper provides an overview of progress in
liposome technology, summarizing the last patents and news
related to liposomes, demonstrating the potential of this
technology for the development of novel neurotherapeutics
and its applications in Alzheimer’s disease and Parkinson’s
disease.
2.Blood-Brain Barrier
The central nervous system (CNS) barriers are composed by
BBB and blood-cerebrospinal ﬂuid barrier (B-CSFB). The
BBB and B-CSFB are a highly specialized brain endothelial
and epithelial structure of the fully diﬀerentiated neurovas-
cular system. These barriers separate components of the
circulating blood from neurons. Moreover, the BBB and B-
CSFB maintain the chemical composition of the neuronal
“milieu,”whichisrequiredfortheproperfunctioningofneu-
ronal circuits, synaptic transmission, synaptic remodelling,
angiogenesis, and neurogenesis in the adult brain.
Three barrier layers regulate molecular exchange at the
interfaces between blood and the neural tissue or its ﬂuid
spaces: the BBB formed by the cerebrovascular endothelial
cells between blood and brain interstitial ﬂuid, the B-CSFB
formed by the choroid plexus epithelium between blood
and ventricular CSF, and the third barrier is the arachnoids
epitheliumbetweenbloodandsubarachnoidCSF.Sinceindi-
vidual neurons are extremely close to the brain capillaries,
rarely at a distance greater than 20μm, of the various CNS
barriers, these barriers exert the greatest control over the
immediate microenvironment of brain cells [23].Journal of Drug Delivery 3
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Figure 1: Schematic representation of the basic structure of unilamellar liposomes (a) and multilamellar liposomes (b). The aqueous core
of the liposome, loaded with the drug, is surrounded by a phospholipid bilayer.
Duetothepresenceofmultipleendogenoustransporters,
BBB allows a selective entry of nutrients and minerals
across it and limits the entry of foreign substances like
d r u g sa sw e l la sn e u r o p h a r m a c e u t i c a la g e n t s .T h i sm a k e st h e
CNS treatment ineﬀective. The conventional drug delivery
systems which release the drug into general circulation
fail to deliver drugs eﬀectively to brain and are, therefore,
not very useful in treating certain diseases that aﬀect CNS
including Alzheimer’s disease, dementia, Parkinson’s disease,
mood disorders, AIDS, and viral and bacterial meningitis.
Therefore, there is a need to develop and design approaches
which speciﬁcally target to brain in a better and eﬀective way
[24]( Figure 2).
Drug delivery to the brain is hindered by the presence
of the CNS barriers. Although the BBB and B-CSFB restrict
the passage of many substances, both are actually selectively
permeable to nutrients necessary for healthy brain function.
In the last decades, despite the advances in drug discovery,
there has been little improvement on the prognosis of
patients with brain diseases, like cancer, neurodegenerative
diseases, or neurological disorders. Often, in clinical trials
it has been found that promising agents in vitro have little
impact on the disease. These disappointing results can be, at
least in part, explained by the inability to deliver therapeutic
agents to the brain across CNS barriers avoiding various
resistance mechanisms to reach the desired targets [25].
3. Liposomes
L i p o s o m e sh a v er e c e i v e dw i d e s p r e a da t t e n t i o na sac a r r i e r
system for therapeutically active compounds, due to their
unique characteristics such as capability to incorporate
hydrophilic and hydrophobic drugs, good compatibility, low
toxicity, lack of immune system activation, and targeted
delivery of bioactive compounds to the site of actions [26].
Liposomes are spherical vesicles that resemble cells in
that they contain an inner hydrophilic core and a relatively
impermeable outer lipophilic phospholipid bilayer [22, 27].
The lipid components of liposomes are predominantly
phosphatidylcholine derived from egg or soybean lecithin
[28]. Liposomes have been shown to provide stable encap-
sulation for various drugs and oﬀer distinct advantages over
unencapsulated agents; thus, liposomes have been proposed
for use in a variety of applications in research, industry, and
medicine, particularly for the use as carriers of diagnostic
and therapeutic compounds (Figure 1).
Liposomes are synthetic lipid spheres composed by fatty
acid on polymers with a bilayered membrane structure
surrounding an aqueous core that can be used to encapsulate
small molecules. Liposomes have the distinct advantages of
being both nontoxic and biodegradable because they are
composed of naturally occurring substances. Biologically
active materials encapsulated within liposomes are protected
to a varying extent from immediate dilution or degradation,
suggesting drug carrier systems for the transport of drugs
and other bioactive capsules to disease-aﬀected organs. The
unique ability of liposomes to entrap drugs both in an aque-
ous and a lipid phase make such delivery systems attractive
for hydrophilic and hydrophobic drugs. Lipophilic drugs are
generally entrapped almost completely in the lipid bilayers
of liposomes, and, since they are poorly water soluble,
problems like loss of an entrapped drug on storage are rarely
encountered. Hydrophilic drugs may either be entrapped
inside the aqueous cores of liposomes or be located in the
external water phase. Noteworthy is that the encapsulation
percentage of hydrophilic drugs by liposomes depends on
the bilayer composition and preparation procedure of the
liposomes [29]. Furthermore, such encapsulation has been
shown to reduce drug toxicity while retaining or improving
the therapeutic eﬃcacy.4 Journal of Drug Delivery
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Figure 2: The antibodies of the immunoliposomes recognise the speciﬁc receptor of the BBB releasing the drug of the immunoliposomes
only close to the targeting cells.
Liposomes can be made from several diﬀerent types of
lipids; however, phospholipids are most commonly used
to generate liposomes as drug carriers. Although liposome
formation is spontaneous when a lipid ﬁlm is mixed with an
aqueous solution, it can also be expedited by applying force
in the form of shaking by using a homogenizer, sonicator, or
an extrusion apparatus [30].
Several other additives may be added to liposomes in
order to modify their structure and properties. For instance,
either cholesterol or sphingomyelin may be added to the
liposomal mixture in order to help stabilize the liposomal
structure and to prevent the leakage of the liposomal
inner cargo [22]. Further, liposomes are prepared from
hydrogenated egg phosphatidylcholine or egg phosphatidyl-
choline, cholesterol, and dicetyl phosphate, and their mean
vesicle sizes were adjusted to about 50 and 100nm.
Conventional liposome formulation is mainly comprised
of natural phospholipids and lipids such as 1,2-distearoryl-
sn-glycero-3-phosphatidyl choline (DSPC), sphingomyelin,
egg phosphatidylcholines and monosialoganglioside. Since
thisformulationismadeupofphospholipidsonly,liposomal
formulations have encountered many challenges, one of the
ones being the instability in plasma [31]. Several attempts to
overcomethesechallengeshavebeenmade,speciﬁcallyinthe
manipulation of the lipid membrane. One of these attempts
focused on the manipulation of cholesterol. Addition of
cholesterol to conventional formulations reduces rapid
release of the encapsulated bioactive compound into the
plasma [32] or 1,2-dioleoyl-sn-glycero-3-phosphoethanola-
mine (DOPE) increases the stability [33].
Although there are many classiﬁcations, depending on
the method of preparation, there are described several
diﬀerent types of liposome vesicles.
(1) Multilamellar vesicles (MLVs): spontaneous forma-
tion of liposomes and gentle shaking produce big
MLVs. This type of liposomes is with multiple
concentric lipid layers, with up to fourteen layers,
each separated by an aqueous solution [34]. MLVs
tend to be present as a heterogeneous mixture, with
vesicle sizes ranging from 500 to 5000nm.
(2) Small unilamellar vesicles (SUVs): homogenization
of MLV can then result in either SUV or large unil-
amellar vesicles (LUVs). SUVs are liposomes whose
structure contains only one lipid layer and whose
average diameter ranges from 25 to 100nm [21, 28].
(3) Large unilamellar vesicles (LUVs): this type of lipos-
omes contains a single lipid layer, and its diameter
can range from 200 to 800nm.
The drug retained and that which leaked were separated
from plasma by gel ﬁltration. On the assumption that
lipid content does not change, the drug released from each
liposome preparation was estimated by a latency percentage
calculated from the drug/lipid concentration ratio of the
liposome preparation. Polyethylene glycol has also been
added to the surface of liposomes in order to prevent liposo-
mal aggregation in solution, to decrease liposomal uptake by
the reticuloendothelial system, and to increase the half-life of
theliposomalformulation.Thesetypesofstericallystabilized
liposomes are called stealth liposomes [35, 36].
Stealth liposome technology is one of the most often
usedliposome-basedsystemsfordeliveryofactivemolecules.
This strategy was achieved simply by modifying the surface
of the liposome membrane, a process that was achieved
by engineering hydrophilic polymer conjugates [37]. The
employed hydrophilic polymers were natural or syntheticJournal of Drug Delivery 5
polymers such as polyethylene glycol (PEG), chitosan, silk-
ﬁbroin, and polyvinyl alcohol (PVA). Although the majority
of hydrophilic polymers conjugate high biocompatibility,
nontoxicity, low immunogenicity, and antigenicity, PEG
remains the most widely used polymer conjugate (Figure 3).
The only shortcoming of liposomes involves their diﬃ-
culty in bypassing certain capillary cells in several organs.
In theory, an encapsulated active drug in a liposomal system
may be released through three possible mechanisms: passive
diﬀusion, vesicle erosion, and vesicle retention, diﬀusion,
erosion, and retention in the circulation. The liposomes
extend then time that medication remains in the blood
stream, prolonging therapeutic actions and reducing toxic
side eﬀects. Larger size or multilamellar liposomes with a
size range of 500–5000nm were the ﬁrst to be eliminated
fromthesystemiccirculationduetophagocytosis[38].Their
problems,however,arebeingrectiﬁedthroughmodiﬁcations
of the size and composition of the lipid components.
3.1. Delivery Strategies of Liposomes. Although liposomes
contain an outer lipophilic membrane that increases their
permeability across membranes, some biological barriers
such as the BBB remain impenetrable. Also, the charge of
the outer membrane aﬀects the distribution and stability of
the liposome. Negatively charged liposomes were believed
to be more rapidly removed from circulation than neutral
or positively charged liposomes; later studies have indicated
that the type of negatively charged lipid aﬀects the rate
of liposome uptake by the reticule-endothelial system. For
example, liposomes containing negatively charged lipids that
are not sterically shielded (phosphatidylserine, phosphatidic
acid, and phosphatidylglycerol) are cleared more rapidly
than neutral liposomes of similar composition. However,
liposomes containing sterically shielded lipids (ganglioside-
GM1 and phosphatidylinositol) are cleared even more slowly
than neutral liposomes [35].
Consequently, scientists have attempted to modify the
liposomal structure in order to improve liposomal pene-
tration across biological membranes and into their target
organs. Targeted liposome-based system was suggested after
conventional stealth liposomes failed to evade uptake of
active molecules by sensitive normal cells or nonspeciﬁc tar-
gets [39]. In addition, a targeted ligand can further increase
the rate of liposomal drug accumulation in the ideal tissue
or cells via overexpressed receptors, antigen and unregulated
selectin [40, 41]. Peptides, proteins, and antibodies have
been mostly studied as a ligand for directing drug-loaded
liposomes into sites of action, due to their molecular struc-
tures, which are essentially composed by known amino acid
sequences (Figure 1).
The main advantage of these structures is the relatively
large quantities of drug that can be incorporated into one
compartment. However, liposome structures present various
problems related to the administration pathway. Orally
administration is diﬃcult because the low pH of the
stomach and the presence of bile salts tend to destabilize
the liposome complex. Liposomes are very sensitive to pH,
light, magnetism, temperature, and ultrasonic waves besides,
liposomes are highly susceptible to destruction via uptake by
the reticule-endothelial system of the macrophages.
A way of protecting liposomes was studied and patented
and consisted in increasing stable bilayers and regulating the
release proﬁle of the liposome [36, 40]. Although liposomes
contain an outer lipophilic membrane that increases their
permeability across membranes, some biological barriers
such as the BBB remain impenetrable. The development of
a suitable liposomal carrier to encapsulate active compounds
is very promising. These liposomes, also named targeted
liposomes, are stable enough to be carried out to the brain
across the BBB, with the appropriate surface characteristics
for an eﬀective targeting and for an active membrane
transport. The main goal is the capacity to release growth
factors,peptides, proteins,orhormones inapreciselocation,
hold the concentration in a physiological range into the
brain, and keep it isolated from immune system attack.
3.2. Other Types of Liposomes
3.2.1. Immunoliposomes. Immunoliposomes are a promis-
ing variant of liposome technique based on an antibody-
conjugated liposomes. Liposomes can carry drugs conju-
gated with monoclonal antibodies and may be directed
against target cells (Figure 2). Although this technique is
still in its infancy, signiﬁcant advances have been made.
Immunoliposomes have been successfully used in vivo to
achieve targeted delivery of tumour-suppressing genes into
tumours, using an antibody fragment against the human
transferrin receptor. Tissue-speciﬁc gene delivery using
immunoliposomes has also been achieved in brain [41].
Chimeric or humanized monoclonal antibodies can reduce
the host response against the therapeutic antibody [42, 43].
The main problem to solve with these antibodies is to
reduce the antigenicity of the immunoliposomes; thus, a
possibility is to remove the Fc portion of the IgG antibody
reducing antigenicity and increasing the therapeutic eﬃcacy.
In addition, cellular internalization of antibodies increases
eﬃcacy of drug delivery, presumably by inducing target cells
to endocytose immunoliposomes. This is the case with the
HER2-targeted immunoliposomes in tumours cells, which
distribute within solid tumours and not simply in the
extracellular space surrounding the tumour blood vessels.
As an attempt to achieve active targeting using high-
aﬃnity binding of antibody to the target, immunolipo-
some, a liposome with antibody attached to its surface,
was developed. Ordinary liposome conjugated by antibody
insuﬃciently avoids the reticule-endothelial system, so a
PEG-modiﬁed liposome is necessary. Two types of approach
were considered; the antibody is conjugated directly to
phospholipid or else to an end of the PEG chain. Experi-
mental results indicated that binding to an end of the PEG
chain is essential to preserve antigen recognition capac-
ity. Antibody-conjugated liposome is also called pendant-
type immunoliposome because of its shape. Pendant-type
immunoliposome is expected to play an important role in
active targeting, since it has long retention due to PEG and
antigenrecognitioncapacitythankstoantibodyconjugation.
But in the case of the IgG antibody, macrophages recognize6 Journal of Drug Delivery
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Figure 3: Schematic representation of diﬀerent types of liposomes. (a) Conventional liposome, (b) conventional liposome tagged directly
with antibodies, (c) stealth liposome coated with a polymeric conjugated, (d) liposome coated with a polymeric conjugated tagged with
antibodies, (e) liposome coated with a speciﬁc ligand.
it and uptake in the liver increases, for macrophages having
Fc receptors. In order to solve this, an immunoliposome
using Fab fragment that lacks Fc region was prepared to
have longer retention after intravenous administration than
IgG-PEG-liposome [44]. The pattern of Fab-PEG-liposome
disappearance in blood was the same as PEG-liposome, and
it had two stages of disappearance, namely, an initial, fast
disappearance due to phagocytosis by macrophages and a
late, slow disappearance. Since longer retention was achieved
by Fab-PEG-liposome, it was shown to avoid the initial
uptake due to phagocytosis.
3.2.2. Virosomes. New generation types of liposomes have
been developed to increase bioactive molecule delivery to
the cytoplasm by escape endosome [45]. New approaches
that employ liposomes as pharmaceutical carriers are viro-
somes. A virosome is another type of liposome formulation;
it comprises noncovalent coupling of a liposome and a
fusogenic viral envelope. Virosomes have been constructed
by combining viral components with nonviral vectors or
by using pseudovirions without viral genome replication.
Viruses, such as inﬂuenza virus, HVJ (hemagglutinating
virus of Japan; Sendai virus), and hepatitis B virus, have
been used in the construction of virosomes. The HVJ-
derived vector is particularly promising due to its highly
eﬃcient delivery of DNA, siRNA, proteins, and anticancer
drugs. Furthermore, the HVJ envelope vector has intrinsic
anti-tumour activities including the activation of multiple
antitumourimmunitiesandtheinductionofcancer-selective
apoptosis [46]. During the last 10 years, active vaccination
with amyloid peptides shows promise for the treatment and
prevention of Alzheimer’s disease. Several studies in trans-
genic mouse models of Alzheimer’s disease have revealed
the potency of vaccination to prevent or even clear amyloid
plaques from mouse brain. Several years ago, Zurbriggen
et al. described an active vaccination method based on
amyloid-beta (1-16) presented on the surface of virosomes,
whichtriggeredadramaticdecreaseinbothamyloid-beta(1-
40) and amyloid-beta (1-42) in a double transgenic mouse
model of Alzheimer’s disease. These uses of virosomes are a
promising antigen carrier system against the neuropathology
of Alzheimer’s disease [47].
3.2.3. Gene-Based Liposomes. The delivery of the large
anionic bioactive DNA across cell has been one of the most
diﬃcult endeavours. DNA is easily degraded by circulatingJournal of Drug Delivery 7
DNA-liposome
Figure 4: A Schematic representation of a DNA-Liposome com-
plex.
and intracellular deoxyribonucleases. Notwithstanding, it
must also be delivered intact across the cell and nucleolar
membranes to the nucleus. Liposomes have, thus, proved
to achieve eﬃcient intracellular delivery of DNA [48].
Such liposomes are prepared from phospholipids with an
amine hydrophilic head group. The amines may be either
quaternary ammonium, tertiary, secondary, or primary, and
the liposomes prepared in this way are commonly referred
to as cationic liposomes since they possess a positive surface
charge at physiological pH (Figure 4).
Although the experimental data have demonstrated that
cationic liposomes can facilitate the transfer of DNA into
live mammalian cells, there are still major problems that
need to be overcome in order to eﬀectively achieve the
goal. These include a reduction in the rapid clearance of
cationic liposomes and the production of eﬃciently targeted
liposomes. At the cellular level, the problems may be over-
comebyimprovingthereceptor-mediateduptakeemploying
appropriate ligands.
4. Liposomes asNeuropharmacological Agents
Liposomes are of a great importance as nanocarriers due
to their relatively large carrying capacity. They have long
been used as drug delivery system to the brain, because the
particles can entrap the compounds and prevent the rapid
elimination or degradation as well as promote the penetra-
tion through the BBB which in turn decreases the eﬀective
dose [49]. In addition, they do not elicit negative biological
responses that generally occur when a foreign material
is introduced in the system. With the pretreatment and
adequate formulation in the brain or in places close to the
brain, the liposomes are nontoxic, nonimmunogenic, non-
carcinogenic, nonthrombogenic, and biodegradable [50].
Based on the same concept the use of liposomes was
proposedforthedeliveryofdiagnosticagentsacrosstheBBB.
For example, it was patented a method using a brain-speciﬁc
liposome targeting vehicle capable of transporting congo red
for neurodiagnostic of Alzheimer’s disease, or transporting
EGF analogues for brain tumours [51]. Recently, Oku
et al. published a new method using PET imaging with
positron emitter-labelled liposomes. This method allows
accumulating liposomes in brain tumours and then detects
small brain tumours with PET scanning [52].
4.1. Liposomes in Parkinson’s Disease. Parkinson’s disease is
a progressive neurodegenerative disorder which involves the
loss of dopaminergic neurons of the substantia nigra [16, 17,
53]. The neuropathological hallmark of Parkinson’s disease
is the progressive degeneration of dopaminergic neurons in
the substantia nigra pars compacta of the brain in addition
to astrocytic gliosis and the presence of numerous other
neuronal systems, associated with widespread occurrence
of intracytoplasmatic alpha-synuclein positive inclusions
known as the Lewy bodies and the Lewy neuritis of neuronal
cells[54].Theubiquitousproteinalpha-synucleinisinvolved
in the pathogenesis of Parkinson’s disease and comprises
protein ﬁlaments of ubiquitin and alpha-synuclein that are
the primary constituent of Lewy’s bodies. Aggregated alpha-
synuclein binds the proteasome and potently inhibits pro-
teasomal activity and the dopaminergic neurotransmission
[55, 56].
In Parkinson’s disease the neurochemical eﬀect is a
decline in dopamine concentrations in the basal ganglia. The
clinical signs include mass loss and gastrointestinal symp-
toms such as indigestion and constipation due to the alpha-
synuclein pathology in the autonomic nerves and ganglia.
Current therapy is essentially symptomatic, and L-DOPA,
the direct precursor of dopamine, is still the most eﬀective
drug for treating bradykinesia and rigidity associated with
the disease. However, during chronic treatment with this
drug, after a good initial response, a variety of complica-
tions emerge. Currently, the laboratories are working with
supplementary agents and antioxidants such as vitamin C
and E that act as neuroprotectants [57]. Also there are many
investigations ongoing with tissue transplantation of fetal
and autologous dopamine containing adrenal medulla and
glial cell line neurotrophic releasing factor (GDNF) into
the cerebral ventricles or basal ganglia or recently inducing
copies of genes into the brain to enhance the production
of dopamine. Although this research showed promise for
the treatment and cure, new approach is needed to test the
eﬃcacy and safety.
The anticholinergic drugs such as biperiden, procycline,
orphenadrine, benzhexol, and benztropine are used to
improve the tremor and stiﬀness to a greater degree than
akinesia and are overall mildly eﬀective [58]. For this reason,
nowadays development of new drugs is increasing and
improving pharmacological and pharmacokinetic properties
compared with L-DOPA [59].
Practical strategies are, therefore, required to develop
a system that can facilitate the transport of new drugs
across the BBB for eﬀective management of Parkinsonism.8 Journal of Drug Delivery
Liposome formulation was developed during the last years as
sustained release systems for drugs to the brain, providing
more eﬀective transport and increasing L-DOPA concen-
tration in the nigrostriatal system after its chemical and
enzymatic degradation [60].
Over 30 years ago, it was developed and characterized
a new system with dopamine-containing liposomes which
exhibited in vitro sustained release of dopamine. These
liposomes were stereotactically implanted into the striatum
of rats subjected to unilateral lesions of the substantia nigra.
This study suggested that dopamine-containing liposomes
can partially ameliorate the deﬁcits associated with a rodent
model of Parkinson’s disease and demonstrate the potential
of this technology as a method for the controlled delivery of
therapeutic agents into discrete areas of the brain [54].
In 2002 an interesting patent was presented with a
method of liposomes containing the pharmacological com-
pound coupled to an antibody-binding fragment which link
to a receptor molecule present on vascular endothelial cells
of the BBB. This antibody fragment allows to bring and ﬁx
the liposome to the wall of the endothelial cells of the BBB
and to release the drug just in the receptors of the BBB,
allowingtheentryofthedrugonlyinthebrain.Theantibody
fragment also has to lack a portion or the entire Fc region
of the molecule to minimize clearance of the composition
by reticuloendothelial system. The receptors used in this
patent were transferrin receptor, insulin receptor, insulin-
like growth factor (IGF)-I receptor or IGF-II receptor [61],
or glucose transport receptor [62]. Another invention based
on the same discovery was presented in 2007; this invention
usedtheliposomesbutincreasingthemeanresidencetimeof
a camptothecin compound in the brain tissue and extending
the beneﬁt of the drug into the brain [63].
It was also published a promising study that compared
neostriatum dopamine concentration after intraperitoneal
administration of diﬀerent drugs for Parkinson’s disease
and the same drugs in liposomal formulations. This study
demonstrated the beneﬁcial formulation of liposomes with
better control, delivery and releases in the striatum of the
anti-Parkinson agents [64].
Glutathione and its associated enzymes form one of the
major antioxidant defense in all cells. There is evidence
that nonliposomal glutathione crosses the BBB but with low
capacity. Recently, a liposomal preparation of glutathione
suppliedinaliposomalformulationwasindicatedaspromis-
ing therapeutic for neuronal maintenance in Parkinson’s
disease, autism, and schizophrenia [65].
Newly, several L-DOPA dimeric prodrugs have been
encapsulated in unilamellar liposomes of phosphatidyl-
choline and cholesterol, and administrated intraperitoneal
via . This formulation showed about 3 fold increase in basal
dopamine levels and a sustained delivery of dopamine in the
striatum compared with the treatment of equimolar admin-
istration of L-DOPA itself. These experiments demonstrated
the better improvement of current drugs only changing the
delivery and encapsulation [66]. One interesting example
happened with GDNF (glial cell-line-derived neurotrophic
factor). However, two open-label trials involving continuous
GDNF infusion into the putamen of Parkinson’s disease
patients were stopped due to lack of good results [67, 68].
AlthoughGDNFdidnot workproperlyintheseclinical trials
GDNF may still be an interesting candidate for the future,
the problems described by the trial could be related to dose
and mode of delivery of the growth factor, and; therefore,
polymer-based drug delivery systems such as liposomes
could be valuable in these respects.
Recently, one study showed the clinical application
of apomorphine, a dopamine receptor agonist. The main
problem of apomorphine is the instability and the need
for frequent injections. This group developed apomorphine
encapsulatedwithinliposomestoprotectitfromdegradation
and enhance the permeability across the BBB. They obtained
promising results; the uptake of liposomes into the brain was
rapid and prolonged, targeting properly the apomorphine
into the damaged brain [69].
4.2. Liposomes in Alzheimer’s Disease. Alzheimer’s disease
is the most common form of dementia in the elderly
population. The mechanisms underlying this disease are not
yet completely clear. Loss of short-term memory, language
impairment and disorientation of time are that looking like
depression symptoms. At the later stages of the disease,
behavioural and psychiatric symptoms develop subsequent
to the decline in the motor functions [70]. Genetic and
biochemical clues suggest that the progressive production
and subsequent accumulation of amyloid-beta plays a role
in the Alzheimer’s disease pathogenesis. There is no drug
to treat Alzheimer’s disease completely. Indeed, strategies
targeting the production and clearance of amyloid-beta
peptide are the most advanced. However, cholinesterase
inhibitors such as rivastigmine are the only agents approved
by the FDA for treatment of this disease [71].
The objective of the last years is using the current drugs
developed with new formulations with nanotechnology.
Based on liposome technology, rivastigmine liposomes were
developed for delivery into the brain through intranasal
route. This study showed that this particular administration
with liposomes signiﬁcantly increased the exposure and the
concentration of the drug into the brain [72]. Recently, it
was developed a new liposome formulations using DPPC
and cholesterol of rivastigmine. This study showed a sig-
niﬁcantly increasing exposure of the drug into the brain
afterintraperitonealandoraladministrationscomparedwith
drug administration without liposomes [73].
Another example which demonstrates the improvement
of the treatment when it is administrated in liposomes was
showed with the quercetin. Oral administration of quercetin
was able to improve learning and memory ability [74, 75];
however, the main problem is the poor absorption and
diﬃculty to pass the BBB. This problematic was trying to
be solved in several papers by Phachonpai et al. in a mouse
model of Alzheimer’s disease where they demonstrated
that nasal administration of Quercetin liposomes attenuated
degeneration of cortical neurons and cholinergic neurons in
hippocampus [76, 77].
A novel liposome delivery system was also developed
for direct transport into olfactory epithelium cells with
polyethylene glycol (PEG)ylated immunoliposomes directedJournal of Drug Delivery 9
against human glioﬁbrillary acidic protein (GFAP). The
handicapoftheseliposomesisbeingincapableofpenetrating
the unimpaired BBB; nevertheless, they may be useful in
delivering drugs to glial brain tumours (which continue to
express GFAP) or to other pathological loci in the brain
withapartiallydisintegratedBBBsuchasAlzheimer’sdisease
[78]. Furthermore, this liposome-mediated transport system
holds promise for the delivery of bioactive substances to
olfactory epithelial cells and modulation of their capacity to
stimulate axonal regeneration.
Following the hypothesis that Alzheimer’s disease is a
conformationaldisease,theneurotoxicamyloid-betapeptide
is formed in anomalous amounts in Alzheimer’s disease.
This peptide is released as monomer and then undergoes
aggregation forming oligomers, ﬁbrils, and plaques in dis-
eased brains. The amyloid-beta aggregates are considered
as possible targets for therapy and diagnosis of Alzheimer’s
disease. Recently it was published a very interesting new
potential treatment for Alzheimer’s disease, using curcumin
that interferes with amyloid plaques encapsulated in lipo-
somes, Mourtas et al. showed an interesting study where
they described the binding of curcumin in the ﬁbrils
interfering in the new formation of plaques. Although it is
a preliminary study, these curcumin liposomes exploit as
new vectors to the diagnostic and therapeutic of Alzheimer’s
disease [79]. another therapy was described by Gobbi et
al. where they realized two types of liposomes and solid
lipid nanoparticles, 145 and 76nm average size, respectively.
Both liposomes functionalized to target amyloid-beta (1-
42) with high aﬃnity. These characteristics make their
liposomes a very promising vector for the targeted delivery
of potential new diagnostic and therapeutic molecules to
be tested in appropriate animal models and clinical trials
[80]. Based on the same concept, Canovi et al. characterized
the binding properties of nanoliposomes decorated with an
anti-amyloid-beta monoclonal antibody obtained in mice
by immunization with amyloid-beta antigen followed by
hybridoma fusion. When they studied by surface plasmon
resonance the liposomes bound to amyloid beta peptides,
they showed markedly bound to amyloid-beta monomers
and ﬁbrils immobilized on the chip. Interestingly, these
liposomes also bound amyloid deposits in postmortem
Alzheimer’s disease brain samples, conﬁrming the poten-
tial of these liposomes for the diagnosis and therapy of
Alzheimer’s disease [81].
Recent in vitro studies with hybrid liposomes suggested
new formulations that are able to restore and maintain
physiologicalmembranepropertiesafterthetoxicityinduced
by amyloid-beta. In the ﬁrst study, they investigated the
inhibitory eﬀects of hybrid liposomes on the accumula-
tion of amyloid beta 1-40 for SH-SY5Y cells. They pre-
pared liposomes composed by phospholipids having various
charged head groups (cationic L-alpha-dimyristoyltrimethyl
ammonium propane (DMTAP), anionic L-alpha-dimyris-
toylphosphatidylserine (DMPS), or zwitterionic L-alpha-
dimyristoylphosphatidylcholine (DMPC)) and polyoxyethy-
lene(23) dodecyl ether (C(12)(EO)(23)), and found that the
cytotoxicityofamyloid-beta(1-42)peptidesontheSH-SY5Y
cells decreased after the treatment with this formulation of
liposomes [82]. In the other in vitro study, they applied
unilamellar liposomes in HEK-APP cells, providing protec-
tion from oxidation and eﬀective incorporation of omega-3
fatty acid docosahexaenoic acid (DHA) into cell membranes
comparing with HEK293 control cells. This study focused
in interesting neuroprotection view using liposomes that
are able to restore and maintain physiological membrane
properties transferring docosanoic acid [83]. These novel
studies with new formulation of hybrid liposomes could be
used as novel medicine for Alzheimer’s disease in the future.
Further, several groups are working in diﬀerent lipo-
some-based vaccines directed toward diﬀerent conforma-
tions of amyloid beta peptide. Interestingly, incorporation of
antigens into biomaterials, such as liposomes, can achieve a
desired vaccine response. A promising study demonstrated
that liposomal vaccine was more eﬀective when the lipo-
somes carried out antibodies against beta-sheet conforma-
tion [84].
5. Conclusions
Nanoscale drug delivery systems including liposomes, poly-
mers, and other nanoparticles provide potential solutions
to improve neurodegeneration therapeutics. Of these drug
deliverysystems,liposome-basedagentswillhavethegreatest
impact in neurology. Current liposomal drugs evolve from
a number of design strategies for the improvement in
biodistribution over free drugs. Reticuloendothelial system-
targeted formulations signiﬁcantly reduce systemic exposure
to high peak levels of free drug but do not facilitate
targetingtobrain.Passiveorphysiologictargetingofdrugsto
brain regions is achievable using long-circulating liposomes,
including pure lipid systems as well as surface-modiﬁed
formulations designed to resist recognition and uptake by
reticuloendothelial system cells.
The neurodegeneration of the Alzheimer’s disease and
Parkinson’s disease has not been beneﬁcially treated by
classical oral therapy. Levodopa for Parkinson’s disease
and rivastigmine for Alzheimer’s disease remain the gold
standard for the therapy. The design and development of an
alternative drug based on new technologies will have a key
roleinthesystemicapplicationofnewdrugs,suchas,growth
factors, peptides or hormones. Nowadays is impossible to
treat correctly many diseases mainly for the localization of
damaged tissue or the complexity of tissue aﬀected. The
complexity of the disease and, many times, the localization
of the tissue damage, diﬃcult the possible treatment, for
example, the brain is isolated by the BBB.
It is well demonstrated that the application of neu-
rotrophic factors is able to modulate neuronal survival and
synaptic connectivity, and it is a promising therapeutic
approach for these neurodegenerative diseases. Although, it
is very diﬃcult to ensure long-term administration into the
brain, liposome technology allows us to facilitate transport
across the BBB. Liposomes have been used clinically as
delivery systems for therapeutic drug delivery of chemother-
apeutic agents, antibiotics, and antifungals. This is because
liposomal preparations have been shown to increase the
margin of safety of many drugs and also their eﬃcacy.10 Journal of Drug Delivery
Among all the applications of liposomal technology, the
development of a suitable liposomal carrier to encapsulate
neuroactive compounds is very promising. These liposomes
are stable enough to be carried to the brain across the BBB,
with the appropriate surface characteristics for an eﬀective
targeting and for an active membrane transport.
Improvements and adjustments to the liposomal formu-
lation are constantly being explored through the addition
of diﬀerent lipids and targeting molecules. For example, in
liposomes lacking cholesterol, high-density lipoprotein can
cause disintegration of the liposome, or in liposomes which
do contain too much cholesterol, high-density lipoprotein
can also cause leakage of contents. The development of novel
therapeutic strategies for neurodegenerative and neurolog-
ical diseases represents one of the biggest unmet medical
needs today. The rapid development of liposome technology
may provide a nearly solution to overcome these diagnostic
and neurotherapeutic challenges for neurodegenerative dis-
eases such as Alzheimer’s disease and Parkinson’s disease.
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